Abstract: Provided herein is a single component sealant formulation (e.g. in a liquid form), methods for its preparation, and use. The formulation includes fibrinogen; vitamin K-dependent clotting zymogens comprising at least Factor II (FII) and Factor X (FX).

Abstract: Provided are methods for lyophilization of an aqueous thrombin solution, thrombin solutions for use in such lyophilization methods, and solid thrombin compositions produced by such methods.

Abstract: The present invention is directed to methods for the production of thrombin from a source of prothrombin using a given BaSO4 reagent as an adsorbent of prothrombin as well as methods for evaluating the suitability of a given BaSO4 reagent for use in preparation of thrombin. In at least one embodiment, the method includes contacting a sample of the given BaSO4 reagent with a source of prothrombin to obtain BaSO4-adsorbed prothrombin, and subsequently evaluating the pro-coagulant activity of the BaSO4-adsorbed prothrombin. In another embodiment, the method includes the step of evaluating relative to the pro-coagulant activity of normal mammalian plasma.

Abstract: Provided are methods for lyophilization of an aqueous thrombin solution, thrombin solutions for use in such lyophilization methods, and solid thrombin compositions produced by such methods.

Abstract: Provided herein are stable liquid sealant formulations comprising fibrin monomers and a reversible fibrin polymerization blocking agent, methods of preparing and using the formulations.

Abstract: A device for administering injections includes a housing having an upper end, a lower end including a bottom surface with an injection needle opening, and an axis extending between the upper and lower ends. The device includes a needle housing with an injection needle. The needle housing is disposed within the housing for moving between a retracted position and an extended position. The device has an injection actuator for commencing an injection cycle including a first stage in which the needle housing and said plunger base are coupled together and move in a first direction along the axis and a second stage in which the needle housing and the plunger base are decoupled from one another so that the plunger base is free to move away from the needle housing in a second direction that is opposite the first direction.

Abstract: Provided is a method for purifying ?-thrombin and for quantifying ?-thrombin and its degradation polypeptides in a liquid proteinatious solution. The method employs a one-step anion exchange chromatography method. The method allows purification and/or quantification of a homogenous post-translationally modified ?-thrombin. The method can also be used for purification and/or quantification of ?-thrombin.

Abstract: The invention relates to a prosthetic for repairing an opening or a defect in a soft tissue, to its preparation and use. The prosthetic of the invention comprises a substrate viscerally-coated with stabilized and non-completely dry fibrin. The prosthetic displays reduced postoperative complications following its implantation.

Abstract: Specific peptides have been discovered that mimic an idiotype of an autoantibody. Such peptides may be formed into polymers. The peptides may be used in pharmaceutical compositions for the treatment of an autoimmune disease together with a pharmaceutically acceptable excipient.

Abstract: Provided is a method for purifying ?-thrombin and for quantifying ?-thrombin and its degradation polypeptides in a liquid proteinatious solution. The method employs a one-step anion exchange chromatography method. The method allows purification and/or quantification of a homogenous post-translationally modified ?-thrombin. The method can also be used for purification and/or quantification of ?-thrombin.

Abstract: Provided are pharmaceutical compositions comprising an anion exchanger and a calcium salt; methods for inducing hemostasis at a site of bleeding by applying to the site of bleeding an effective amount of the compositions; and methods of preparation of the compositions.

Abstract: The invention relates to a viral-safe platelet extract, to its preparation and use. The extract comprises a mixture of biologically active platelet derived factors. Advantageously, the extract comprises a balanced proportion of the factors and is non-clottable.

Abstract: The invention relates to a proteolytic enzyme which is capable of forming fibrin when it reacts with fibrinogen, a fibrin-glue kit and a fibrin-glue formulation comprising an enzymatically-permissive concentration of a visualization agent and to their use in methods for prevention and/or reduction of adhesions and/or methods for promotion of blood coagulation sealing or filling body surfaces.

Abstract: Provided are pharmaceutical foam compositions comprising a peptone, a peptide hydrolysate or an enzymatically-hydrolyzed protein prepared by enzymatic hydrolysis of a full-length protein; methods of preparation and uses thereof.

Abstract: The invention relates to a storage-stable aqueous sealant formulation comprising a blood derived fibrinogen concentrate, a divalent cation and factor XIa.

Abstract: A method is described for the measurement of thrombin activity in the presence of fibrinogen, or for the measurement of the functionality of fibrinogen in the presence of thrombin.

Abstract: The present invention is directed to methods for the production of thrombin from a source of prothrombin using a given BaSO4 reagent as an adsorbent of prothrombin as well as methods for evaluating the suitability of a given BaSO4 reagent for use in preparation of thrombin. In at least one embodiment, the method includes contacting a sample of the given BaSO4 reagent with a source of prothrombin to obtain BaSO4-adsorbed prothrombin, and subsequently evaluating the pro-coagulant activity of the BaSO4-adsorbed prothrombin. In another embodiment, the method includes the step of evaluating relative to the pro-coagulant activity of normal mammalian plasma.

Abstract: The invention relates to a viral inactivated biological liquid or dry mixture and to its preparation. Principally, the invention relates, but is not limited, to a mixture derived from a platelet source.

Abstract: Provided herein are stable liquid sealant formulations comprising fibrin monomers and a reversible fibrin polymerization blocking agent, methods of preparing and using the formulations.

Abstract: Provided herein is a single component sealant formulation (e.g. in a liquid form), methods for its preparation, and use. The formulation includes fibrinogen; vitamin K-dependent clotting zymogens comprising at least Factor II (FII) and Factor X (FX).